Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | ANPEP | P15144 | 3/20 | 0.40 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.40 |
| ▸ | DNPEP | Q9ULA0 | 2/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5144576 | 1.00 | BLM (0.50) | BLMLMNAANPEPRNPEPDNPEP | |
| SCHEMBL28122965 | 0.88 | ANPEP (0.38) | ANPEPRNPEPDNPEPRAB9ASMN1; SMN2 | |
| SCHEMBL13937744 | 0.84 | ANPEP (0.40) | BLMANPEPRNPEPDNPEPMEN1 | |
| SCHEMBL801092 | 0.83 | — | — | |
| SCHEMBL14024980 | 0.82 | DPP7 (0.40) | BLMLMNAANPEPRNPEPDNPEP | |
| SCHEMBL19468535 | 0.80 | EPHX1 (0.43) | ANPEPRNPEPDNPEPMMP8 | |
| SCHEMBL19468498 | 0.80 | EPHX1 (0.43) | ANPEPRNPEPDNPEPMMP8 | |
| SCHEMBL8432422 | 0.80 | EPHX1 (0.43) | ANPEPRNPEPDNPEPMMP8 | |
| SCHEMBL19468504 | 0.80 | EPHX1 (0.43) | ANPEPRNPEPDNPEPMMP8 | |
| SCHEMBL19468450 | 0.80 | EPHX1 (0.43) | ANPEPRNPEPDNPEPMMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230404921-A1 | LYOTROPIC LIQUID CRYSTALLINE PHASE PARTICLE | ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY (AU) | 2023-12-21 | — | — | US | disclosed |
| WO-2023225722-A1 | LIPID NANOCARRIER VACCINE | ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY (AU) | 2023-11-30 | — | — | WO | disclosed |
| US-20230277463-A1 | LIQUID CRYSTALLINE DOSAGE FORM FOR ADMINISTERING A STATIN | ZEENAR ENTERPRISES PTY LTD (AU) | 2023-09-07 | — | — | US | disclosed |
| EP-4236916-A1 | LYOTROPIC LIQUID CRYSTALLINE PHASE PARTICLE | Royal Melbourne Institute of Technology (AU) | 2023-09-06 | — | — | EP | disclosed |
| US-11638698-B2 | Liquid crystalline dosage form for administering a statin | ZEENAR ENTERPRISES PTY LTD (AU) | 2023-05-02 | — | — | US | disclosed |
| WO-2022087686-A1 | LYOTROPIC LIQUID CRYSTALLINE PHASE PARTICLE | ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY (AU) | 2022-05-05 | — | — | WO | disclosed |
| US-20210369623-A1 | COMPOSITION THAT FORMS LIQUID CRYSTALLINE PARTICLES | ZEENAR ENTERPRISES PTY LTD (AU) | 2021-12-02 | — | — | US | disclosed |
| US-20210145737-A1 | FAST DISINTEGRATING TABLET | ZEENAR ENTERPRISES PTY LTD (AU) | 2021-05-20 | — | — | US | disclosed |
| US-20210145730-A1 | PROCESS FOR PREPARING AN ORAL DISINTEGRATING DOSAGE FORM | ZEENAR ENTERPRISES PTY LTD (AU) | 2021-05-20 | — | — | US | disclosed |
| US-20210145752-A1 | LIQUID CRYSTALLINE DOSAGE FORM FOR ADMINISTERING A STATIN | ZEENAR ENTERPRISES PTY LTD (AU) | 2021-05-20 | — | — | US | disclosed |
| WO-2018191793-A1 | FAST DISINTEGRATING TABLET | ZEENAR ENTERPRISES PTY LTD (AU) | 2018-10-25 | — | — | WO | disclosed |
| WO-2018191794-A1 | LIQUID CRYSTALLINE DOSAGE FORM FOR ADMINISTERING A STATIN | ZEENAR ENTERPRISES PTY LTD (AU) | 2018-10-25 | — | — | WO | disclosed |
| US-20070108405-A1 | Compositions and methods for delivery of biologically active agents | FH FAULDING & CO., LTD. (AU) | 2007-05-17 | — | — | US | disclosed |
| CN-1933813-A | Compositions and methods for delivery of biologically active agents | FH FAULDING & CO LTD (AU) | 2007-03-21 | — | — | CN | disclosed |
| EP-1534669-A4 | UREA-, GLYCERATE- AND, HYDROXYAMIDE-HEADED HYDROCARBON CHAIN LYOTROPIC PHASES FORMING SURFACTANTS | MAYNE PHARMA INT PTY LTD (AU) | 2007-03-14 | — | — | EP | disclosed |
| EP-1667656-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOLOGICALLY ACTIVE AGENTS | FH Faulding & Co. Limited (AU) | 2006-06-14 | — | — | EP | disclosed |
| US-20050249665-A1 | Urea-, glycerate- and, hydroxyamide-headed hydrocarbon chain lyotropic phases forming surfactants | DBL AUSTRALIA PTY LTD. (AU) | 2005-11-10 | — | — | US | disclosed |
| EP-1534669-A1 | UREA-, GLYCERATE- AND, HYDROXYAMIDE-HEADED HYDROCARBON CHAIN LYOTROPIC PHASES FORMING SURFACTANTS | DBL Australia PTY. LTD. (AU) | 2005-06-01 | — | — | EP | disclosed |
| WO-2005021046-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOLOGICALLY ACTIVE AGENTS | FH FAULDING & CO LTD (AU) | 2005-03-10 | — | — | WO | disclosed |
| WO-2004022530-A1 | UREA-, GLYCERATE- AND, HYDROXYAMIDE-HEADED HYDROCARBON CHAIN LYOTROPIC PHASES FORMING SURFACTANTS | DBL AUSTRALIA PTY LTD (AU) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210145730-A1 | PROCESS FOR PREPARING AN ORAL DISINTEGRATING DOSAGE FORM | ACIN1, SKP1, OCIAD1 | BLM 2401/4885LMNA 2093/4885ANPEP 4435/4885 |
| US-20230277463-A1 | LIQUID CRYSTALLINE DOSAGE FORM FOR ADMINISTERING A STATIN | HMGCR, LIPA, NPC1L1 | BLM 288/4885LMNA 687/4885ANPEP 2921/4885 |
| US-20050249665-A1 | Urea-, glycerate- and, hydroxyamide-headed hydrocarbon chain lyotropic phases forming surfactants | LIPA, HDHD5, UGCG | BLM 1559/4885LMNA 208/4885ANPEP 2476/4885 |
| US-20210145752-A1 | LIQUID CRYSTALLINE DOSAGE FORM FOR ADMINISTERING A STATIN | HMGCR, LIPA, NPC1L1 | BLM 288/4885LMNA 687/4885ANPEP 2921/4885 |
| US-20210369623-A1 | COMPOSITION THAT FORMS LIQUID CRYSTALLINE PARTICLES | AQP1, OSTC, AQP3 | BLM 1975/4885LMNA 2760/4885ANPEP 3734/4885 |
| US-20210145737-A1 | FAST DISINTEGRATING TABLET | SI, DSC1, STOM | BLM 936/4885LMNA 1532/4885ANPEP 3747/4885 |
| US-11638698-B2 | Liquid crystalline dosage form for administering a statin | HMGCR, LIPA, NPC1L1 | BLM 288/4885LMNA 687/4885ANPEP 2921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.